Somatostatin Receptor Expression on [68Ga]Ga-DOTATATE PET Among Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas: A Prospective Study - PubMed
5 hours ago
- #SSTR expression
- #DOTATATE PET
- #neuroendocrine carcinoma
- Only 13% of patients with extrapulmonary neuroendocrine carcinomas (NECs) showed uniform, strong SSTR expression on [68Ga]Ga-DOTATATE PET.
- The study prospectively compared [68Ga]Ga-DOTATATE PET with [18F]FDG PET in 30 metastatic extrapulmonary NEC patients, assessing SSTR avidity.
- Primary tumors varied, with pancreas, colon/rectum, uterus, and unknown sites; histologic subtypes included small cell, large cell, and mixed types.
- Results indicate avid SSTR expression is less common in unselected NEC patients, contrasting with earlier retrospective reports suggesting higher rates.
- The findings highlight limited SSTR expression in poorly differentiated extrapulmonary NECs, impacting potential targeted therapy options like peptide receptor radionuclide therapy.